Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (1839)	11/5/2001 5:09:05 AM
From: nigel bates	Read Replies (1) \| Respond to of 3202

Agilent Technologies and Incyte Genomics Announce Patent Portfolio Agreement PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 5, 2001-- Agilent Technologies Inc. (NYSE:A - news) and Incyte Genomics Inc. (Nasdaq:INCY - news), the leading genomic information company, today announced a comprehensive licensing agreement that gives Agilent access to Incyte's key microarray and gene expression patents and strengthens Agilent's position as a major manufacturer of printed DNA microarrays. Included in the agreement are licenses to the nucleic acid linear amplification patents of Eberwine, Van Gelder, Wang and others. Also included are the patent portfolio of Shalon and Brown covering DNA microarrays, their manufacture and use, and the Augenlicht patent covering the use of gene expression arrays in cancer research and diagnosis. Additionally, Incyte has exclusively licensed Agilent under its comprehensive patent portfolio covering inkjet array manufacture. This portfolio includes the inventions of Gamble, Theriault, Baldeschwieler and Winder for in situ synthesis of nucleic acid microarrays and adds to the considerable inkjet patent portfolio of Agilent, which also includes licenses to Hewlett-Packard Company and Canon inkjet intellectual property. The exclusive license of Incyte's inkjet patent portfolio and the license to the Shalon/Brown patents will allow Agilent greater flexibility in the design of instruments for the manufacture of printed microarrays. The license to Incyte's gene expression intellectual property, combined with Agilent's own sample preparation technologies, will allow Agilent to provide its customers with the freedom to use ``the gold standard'' amplification methodologies for their various application needs. Further financial details of the license agreement were not disclosed. ``We are pleased to add the Incyte patents to the already extensive portfolio of Agilent patents and patent licenses,'' said Barney Saunders, vice president and general manager of Agilent's Bio-Research Solutions. ``These patents will consolidate and strengthen Agilent's position as a major manufacturer of printed DNA microarrays and as a supplier of reagents and kits for sample preparation.'' ``These technology licensing agreements underscore the growing collaborative relationship between Incyte and Agilent, which includes our earlier agreement regarding the supply of cDNA clones and Lifeseq data for Agilent-manufactured arrays,'' said Roy A. Whitfield, chief executive of Incyte. ``Incyte is pleased that Agilent's customers will now have the benefit of Incyte's array technologies as well as Incyte's content.'' About Incyte Genomics, Inc. Incyte Genomics, Inc. has developed the leading integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, and related reagents. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. In addition, Incyte has the largest portfolio of issued United States patents covering human full-length genes and the proteins they encode and is leveraging its intellectual property position to be a leader in therapeutic discoveries. For more information, visit Incyte's web site at incyte.com. About Agilent Technologies Agilent Technologies Inc. (NYSE:A - news) is a global technology leader in communications, electronics and life sciences. The company's 43,000 employees serve customers in more than 120 countries. Agilent had net revenue of $9.4 billion in fiscal year 2000, as restated to reflect the sale of its healthcare business. Information about Agilent is available on the Web at www.agilent.com.